Recommended Pages at press.bayerhealthcare.com
Bayer HealthCare - New England Journal of Medicine Publishes Results of Landmark ROCKET AF Study of Bayer’s Xarelto® (Rivaroxaban)
press.bayerhealthcare.com — “Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. The company combines the global activities of the divisions Animal Health, Bayer Schering Pharma, Consumer Care and Diabetes Care. More than 50,000 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality ” View full resource at press.bayerhealthcare.com
Most Recently Shared on August 11, 2011 at 6:39 am By:
New England Journal of Medicine Publishes Results of Landmark ROCKET AF Study of Bayer’s Xarelto® (Rivaroxaban) http://t.co/u118vol
Bayer HealthCare - Bayer and Trius Therapeutics to develop and commercialize new antibiotic for specific skin infections and pneumonia
press.bayerhealthcare.com — “Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. The company combines the global activities of the divisions Animal Health, Bayer Schering Pharma, Consumer Care and Diabetes Care. More than 50,000 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality ” View full resource at press.bayerhealthcare.com
Most Recently Shared on July 28, 2011 at 7:01 am By:
Bayer and Trius Therapeutics to develop and commercialize new antibiotic for specific skin infections and pneumonia http://t.co/OEcpjR0
Bayer HealthCare - Phase III J-ROCKET AF Study of Bayer’s Xarelto® (rivaroxaban) Meets Primary Endpoint
press.bayerhealthcare.com — “Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. The company combines the global activities of the divisions Animal Health, Bayer Schering Pharma, Consumer Care and Diabetes Care. More than 50,000 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality ” View full resource at press.bayerhealthcare.com
Most Recently Shared on July 25, 2011 at 4:52 am By:
Phase III J-ROCKET AF Study of Bayer’s Xarelto® (rivaroxaban) Meets Primary Endpoint http://t.co/KROMmZ3 Not intended for U.S. and UK Media
Bayer HealthCare - FDA Approves Xarelto® (rivaroxaban tablets) for the Prophylaxis of Deep Vein Thrombosis Which May Lead to a Pulmonary Embolism in Patients Undergoing Knee or Hip Replacement Surgery
press.bayerhealthcare.com — “Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. The company combines the global activities of the divisions Animal Health, Bayer Schering Pharma, Consumer Care and Diabetes Care. More than 50,000 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality ” View full resource at press.bayerhealthcare.com
Most Recently Shared on July 3, 2011 at 6:25 pm By:
FDA Approves Xarelto® for the Prophylaxis of Deep Vein Thrombosis ......... http://t.co/yn1AQsl
Bayer HealthCare - VEGF Trap-Eye Submitted for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration in Japan
press.bayerhealthcare.com — “Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. The company combines the global activities of the divisions Animal Health, Bayer Schering Pharma, Consumer Care and Diabetes Care. More than 50,000 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality ” View full resource at press.bayerhealthcare.com
Most Recently Shared on June 29, 2011 at 7:14 am By:
VEGF Trap-Eye Submitted for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration in Japan http://t.co/9dEbzKz
Bayer HealthCare - Major Subgroup Analysis Shows Bayer’s Rivaroxaban is Highly Effective in the Prevention of Recurrent Strokes
press.bayerhealthcare.com — “Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. The company combines the global activities of the divisions Animal Health, Bayer Schering Pharma, Consumer Care and Diabetes Care. More than 50,000 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality ” View full resource at press.bayerhealthcare.com
Most Recently Shared on May 25, 2011 at 10:35 am By:
Major Subgroup Analysis Shows Bayer’s Rivaroxaban is ....... http://bit.ly/kNKt1D
Bayer HealthCare - Phase II study with riociguat from Bayer shows promising results in patients with pulmonary hypertension owing to COPD
press.bayerhealthcare.com — “Bayer HealthCare, a subsidiary of Bayer AG, is one of the world--™s leading, innovative companies in the healthcare and medical products industry. The company combines the global activities of the divisions Animal Health, Bayer Schering Pharma, Consumer Care and Diabetes Care. More than 50,000 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and ” View full resource at press.bayerhealthcare.com
Most Recently Shared on May 19, 2011 at 6:47 am By:
Phase II study with riociguat from Bayer shows promising results in patients with pulmonary hypertension owing to COPD http://bit.ly/kRyQnG
